Target intelligence / Profile preview

Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 16 (ST13P16)

Target: ST13P16
Molecular classification: Pseudogene

Overview

ST13P16 is a processed pseudogene related to the suppression of tumorigenicity 13 (colon carcinoma) gene, which encodes an Hsp70 interacting protein. Pseudogenes like ST13P16 are non-protein-coding genomic sequences; they typically arise by duplication or retrotransposition of protein-coding genes, and accumulate disabling mutations. They do not encode functional proteins, but their transcripts may, in some cases, regulate parental gene expression through RNA-mediated mechanisms such as antisense interactions or small RNA generation. No evidence suggests that ST13P16 is a direct therapeutic or diagnostic target, and it is not traditionally considered in drug discovery efforts.

Other names: Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 16

Biological functions

Possible regulation of parental gene expression through competing endogenous RNA (ceRNA) activity or generation of small RNAs, but specific function for ST13P16 is unknown

Disease associations

No known direct role in disease, but pseudogenes overall can contribute to disease via regulation of parental genes, most prominently in cancer

Beyond the preview

Go deeper on Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 16 (ST13P16).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 16 (ST13P16).

Explore the full profile